K PHARMA,INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 707 JPY | +2.46% |
|
+14.03% | -1.81% |
| Apr. 13 | Certain Common Stock of K Pharma,Inc. are subject to a Lock-Up Agreement Ending on 13-APR-2024. | CI |
| 2023 | K Pharma,Inc. has completed an IPO in the amount of ¥1.596 billion. | CI |
| 1 day | +2.46% | ||
| 1 week | +14.03% | ||
| 1 month | +11.34% | ||
| 3 months | +20.65% | ||
| 6 months | +5.84% | ||
| Current year | -1.81% |
1 week
620.00
711.00
1 month
590.00711.00
Current year
550.00742.00
1 year
531.00980.00
3 years
531.00980.00
5 years
531.00980.00
10 years
531.00980.00
| Managers | Title | Age | Since |
|---|---|---|---|
Masaya Nakamura
FOU | Founder | 62 | 16-10-31 |
Komei Fukushima
FOU | Founder | 63 | 16-10-31 |
Hideyuki Okano
FOU | Founder | 65 | 16-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hideyuki Okano
FOU | Founder | 65 | 16-10-31 |
Masato Matsumoto
DFI | Director of Finance/CFO | 48 | 21-08-31 |
Keiko Hatta
BRD | Director/Board Member | 64 | 22-10-31 |
K Pharma Inc is a Japan-based company mainly engaged in the pharmaceutical business. The Company operates through a single segment of research, development, manufacture, and sale of pharmaceuticals, among others. The Company is engaged in induced pluripotent stem cell (iPS) drug discovery business. Neural progenitor cells, the cells that form the basis of nerves, are created from iPS cells, cryopreserved, and then 200000 cells are transplanted by injection into the site of a patient's spinal cord injury. The Company is also engaged in the research, development, manufacture and sale of regenerative medicine products.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -1.81% | 52.19M | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- 4896 Stock
